甲孕酮联合CAP方案治疗晚期非小细胞肺癌的临床观察

Clinical Analysis of Mderoxyprogesterone acetate plus CAP regimen in patients with advanced non-small cell lung cancer

目的对甲孕酮联合CAP方案与单纯使用CAP方案治疗晚期非小细胞肺癌的疗效,生活质量和毒性等情况进行临床观察和比较。方法59例晚期非小细胞肺癌患者随机分成两组,联合组(30例):甲孕酮每次250mg口服,每天3次,CTX400mg/(m·2d),静脉注射,第一天;ADM40mg/(m2·d),静脉注射,第一天;DDP40mg/(m·2d),静脉脉注射,第一天;单化疗组:单纯予同上CAP方案。结果两组疗效(CR+PR)分别为联合组28.3%,单化组23.8%,P>0.05;中位生存期联合组33周,单化疗组25周,P<0.01;毒性反应联合组较单化疗组轻,P<0.01。结论甲孕酮联合CAP方案与单纯使用CAP方案治疗晚期非小细胞肺癌的疗效无显著差异,但前者中位生存期长,患者生活质量明显提高,毒副反应轻。

Objective To compare the effect, toxicity and quality of life between MPA-CAP regimen and CAP regimen alone in patients with advanced non-small cell lung cancer. Methods 59 patients were divided randomly into two groups. MPA-CAP group： all patients took medroxyprogesterone acetate 250 mg twice a day; CTX 400 mg/m^2·d given intravenously on the first day; ADM 40 mg/m^2·d given intravenously on the first day; DDP 40 mg/m^2·d given intravenously on the first day; CAP group： CAP regimen alone. Results The objective response rates （CR＋PR）were 28.3% in group MPA-CAP and 23.8% in group CAP respectively （P〉0.05）.The median survival was 33 weeks in group MPA-CAP and 25 weeks in group CAP（P〈0.01 ）leukopenia, nausea and vomiting in group CAP were more serious than those in group MPA-CAP （P〈0.01）.Conclusion MPA-CAP regimen result in lower toxicity, longer median survival and better quality of life than those of CAP regimen, though there was no significant difference on the objective response rate between the two groups.